JZP385

DRUG2 trials

Sponsors

Cavion Inc., Jazz Pharmaceuticals

Conditions

Essential TremorParkinson's Disease

Phase 2

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

CompletedNCT05122650

Jazz PharmaceuticalsEssential Tremor

Start: 2021-12-06End: 2024-05-30Updated: 2025-07-24

A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s Disease

CompletedCTIS2024-515177-94-00

Cavion Inc.Parkinson's Disease

Start: 2023-06-21End: 2024-11-01Target: 132Updated: 2024-11-27